Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies

J Pharm Biomed Anal. 2006 Sep 18;42(2):253-60. doi: 10.1016/j.jpba.2006.04.010. Epub 2006 Jun 9.

Abstract

A method has been developed for the quantitation of ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma. ABT-751 and metabolites were separated from endogenous material on a C18 column with acetonitrile-ammonium acetate (2 mM) mobile phase containing formic acid (0.1%, v/v) using isocratic flow for 5 min. The analytes were monitored by tandem-mass spectrometry. Calibration curves were generated over the range of 20-5,000 ng/ml for ABT-751, ABT-751 glucuronide, and ABT-751 sulfate. A 20,000 ng/ml sample that was diluted 1:10 (v/v) with plasma was accurately quantitated. The method has been successfully applied to study the plasma pharmacokinetics of ABT-751 in humans.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Antimitotic Agents / blood*
  • Antimitotic Agents / chemistry
  • Calibration
  • Chromatography, Liquid / methods*
  • Clinical Chemistry Tests
  • Humans
  • Molecular Structure
  • Reference Standards
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Sulfonamides / blood*
  • Sulfonamides / chemistry
  • Tandem Mass Spectrometry / methods*

Substances

  • ABT751
  • Antimitotic Agents
  • Sulfonamides